Suzhou Evopoint Biosciences

Evopoint Biosciences is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to the discovery and development of transformative medicines for oncology, infectious diseases, and metabolic disorders. The company leverages its proprietary technology platforms to build a robust pipeline of small molecule and biologic candidates. Its lead programs include EVP8208, a next-generation XPO1 inhibitor, and EVP02, a KRAS G12C inhibitor, both currently in clinical development. Evopoint aims to address global unmet medical needs through innovative science and strategic collaborations. The company is backed by prominent life science investors including Hillhouse Capital and Lilly Asia Ventures. With operations in Suzhou and Shanghai, Evopoint is positioned to advance its candidates through global clinical trials.